The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors

INTRODUCTION: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Grossberg, George T., Manes, Facundo, Allegri, Ricardo F., Gutiérrez-Robledo, Luis Miguel, Gloger, Sergio, Xie, Lei, Jia, X. Daniel, Pejović, Vojislav, Miller, Michael L., Perhach, James L., Graham, Stephen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680656/
https://www.ncbi.nlm.nih.gov/pubmed/23733403
http://dx.doi.org/10.1007/s40263-013-0077-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680656/
https://www.ncbi.nlm.nih.gov/pubmed/23733403
http://dx.doi.org/10.1007/s40263-013-0077-7

Ejemplares similares